Paul D. Stein, MD, Russell D. Hull, MBBS, MSc, Fadi Matta, MD, Abdo Y

Slides:

Advertisements

Similar presentations

Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effect of Clopidogrel Pretreatment Before Percutaneous.

Advertisements

Low-Dose Aspirin in Patients with Stable Cardiovascular Disease: A Meta-analysis Jeffrey S. Berger, MD, MS, David L. Brown, MD, Richard C. Becker, MD The.

Volume 355, Issue 9212, Pages (April 2000)

Paul D. Stein, MD, Fadi Matta, MD, Mary J. Hughes, DO

Steven Baroletti, PharmD, MBA, Shelley Hurwitz, PhD, Nicole A. S

Copyright © 2003 American Medical Association. All rights reserved.

Fig. 2. Comparative efficacy of thromboprophylaxis interventions in the prevention of deep vein thrombosis (DVT). (A) Estimated odds ratios (ORs) and 95%

Thomas F. O’Donnell, MD, Joseph Lau, MD Journal of Vascular Surgery

Copyright © 2012 American Medical Association. All rights reserved.

From: Low-Molecular-Weight Heparins Compared with Unfractionated Heparin for Treatment of Acute Deep Venous Thrombosis: A Cost-Effectiveness Analysis Ann.

Volume 373, Issue 9679, Pages (June 2009)

From: Low-Molecular-Weight Heparins Compared with Unfractionated Heparin for Treatment of Acute Deep Venous Thrombosis: A Cost-Effectiveness Analysis Ann.

Copyright © 2000 American Medical Association. All rights reserved.

Long-term Low-Molecular-Weight Heparin versus Usual Care in Proximal-Vein Thrombosis Patients with Cancer Russell D. Hull, MBBS, MSc, Graham F. Pineo,

Russell D. Hull, MBBS, MSc, Graham F. Pineo, MD, Rollin F

Perioperative Blood Transfusion Is Associated With Worse Clinical Outcomes in Resected Lung Cancer Ting Wang, MD, Lili Luo, MD, He Huang, MD, Jingrui.

by Nadine Martel, James Lee, and Philip S. Wells

Duration of Dual Antiplatelet Therapy in Patients with an Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Chirag Bavishi, MD, MPH,

Impact of More Restrictive Blood Transfusion Strategies on Clinical Outcomes: A Meta- analysis and Systematic Review Shelley R. Salpeter, MD, Jacob S.

How Well Are Pulses Measured

Nikolaos P. Polyzos, M. D. , Christina I. Messini, M. D. , Evangelos G

Alexander A. Leung, MD, MPH, Finlay A. McAlister, MD, MSc, Samuel R. G

Samy Suissa, PhD, Abbas Kezouh, PhD, Pierre Ernst, MD, MSc

Russell D. Hull, MBBS, MSc, Jane Liang, MSc, Grace Townshend, MSc

Venous Thromboembolism with Chronic Liver Disease

Paul D. Stein, MD, Fadi Matta, MD, Daniel C. Keyes, MD, Gary L

Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation Giulia Renda, MD, PhD, Marco.

New oral anticoagulants—what the cardiothoracic surgeon needs to know

Steven Baroletti, PharmD, MBA, Shelley Hurwitz, PhD, Nicole A. S

Paul D. Stein, MD, Afzal Beemath, MD, Frederick A

Predictors and Causes of Long-Term Mortality in Elderly Patients with Acute Venous Thromboembolism: A Prospective Cohort Study Nicolas Faller, MD, PhD,

Caprini venous thromboembolism risk assessment permits selection for postdischarge prophylactic anticoagulation in patients with resectable lung cancer

Don't look now! Risk stratify first

Succinct Review of the New VTE Prevention and Management Guidelines

Marc Carrier, MD, MSc, Alok A

Paul D. Stein, MD, Fadi Matta, MD, Daniel C. Keyes, MD, Gary L

Long-term Low-Molecular-Weight Heparin versus Usual Care in Proximal-Vein Thrombosis Patients with Cancer Russell D. Hull, MBBS, MSc, Graham F. Pineo,

Russell D. Hull, MBBS, MSc, Graham F. Pineo, MD, Rollin F

John Fanikos, RPh, MBA, Amanda Rao, BS, Andrew C

Influence of Renal Function on the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Non–Vitamin K Antagonist Oral Anticoagulants Matthew R.

Antibiotic Therapy and 48-Hour Mortality for Patients with Pneumonia

Robert Goulden, MBBS, MSc, MPhil, MA The American Journal of Medicine

Sabina Hunziker, MD, MPH, Jennifer Stevens, MD, MS, Michael D

Volume 373, Issue 9679, Pages (June 2009)

Muhammad Amer, MD, MHS, FACP, Rehan Qayyum, MD, MHS

Do Factor V Leiden and Prothrombin G20210A Mutations Predict Recurrent Venous Thromboembolism in Older Patients? Marie Méan, MD, Andreas Limacher, PhD,

Perioperative Blood Transfusion Is Associated With Worse Clinical Outcomes in Resected Lung Cancer Ting Wang, MD, Lili Luo, MD, He Huang, MD, Jingrui.

Carmelo V. Venero, MD, Paul D. Thompson, MD, Antonio B. Fernandez, MD

Fish Consumption and Colorectal Cancer Risk in Humans: A Systematic Review and Meta-analysis Shengjun Wu, MD, PhD, Bin Feng, MD, Kai Li, MD, Xia Zhu,

Migraine Headache and Ischemic Stroke Risk: An Updated Meta-analysis

Paul D. Stein, MD, Fadi Matta, MD, Muzammil H

Thomas F. O’Donnell, MD, Joseph Lau, MD Journal of Vascular Surgery

Carlos Aguilar, MD, Valentin del Villar, MD

Variation in thromboembolic complications among patients undergoing commonly performed cancer operations Randall R. De Martino, MD, MS, Philip P. Goodney,

Yousef Rezaei, MD American Journal of Kidney Diseases

Scope of Problem of Pulmonary Arterial Hypertension

Shannon M. Dunlay, MD, MS, Quinn R. Pack, MD, Randal J

Prevalence and Risk Factors for Erectile Dysfunction in the US

Age Differences in Treatment and Control of Hypertension in US Physician Offices, : A Serial Cross-sectional Study Anna Gu, MD, PhD, Yu Yue,

One-way Versus Two-way Text Messaging on Improving Medication Adherence: Meta- analysis of Randomized Trials David S. Wald, MD, FRCP, Shahena Butt, MSc,

A Post-cure Complication

Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20 536 high-risk individuals: a randomised.

Screening and Treatment of Vitamin D Deficiency on Hospital Admission: Is There a Benefit for Medical Inpatients? Lena Grädel, MD, Meret Merker, BMSc,

Antiphospholipid antibodies associated with recurrent pregnancy loss: Prospective, multicenter, controlled pilot study comparing treatment with low-molecular-weight.

Direct Observation of Residents: A Model for an Assessment System

Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation Giulia Renda, MD, PhD, Marco.

Acquired Generalized Lipodystrophy Following Immune Thrombocytopenia

Hospital Costs of Acute Pulmonary Embolism

Emily G. McDonald, MD, MSc, Ramy R. Saleh, MD, Todd C. Lee, MD, MPH

Paul D. Stein, MD, Fadi Matta, MD The American Journal of Medicine

Presentation transcript:

Incidence of Thrombocytopenia in Hospitalized Patients with Venous Thromboembolism Paul D. Stein, MD, Russell D. Hull, MBBS, MSc, Fadi Matta, MD, Abdo Y. Yaekoub, MD, Jane Liang, MSc The American Journal of Medicine Volume 122, Issue 10, Pages 919-930 (October 2009) DOI: 10.1016/j.amjmed.2009.03.026 Copyright © 2009 Elsevier Inc. Terms and Conditions

Figure 1 Proportional effects of unfractionated heparin (UFH) and low-molecular weight heparin (LMWH) on heparin-associated thrombocytopenia in medical and surgical patients who received prophylaxis. Summary and individual study results are shown. All studies were prospective with >100 patients in each arm. Black squares = point estimates (with area proportional to number of events) and horizontal lines = 95% confidence interval (CI) for observed effects in different subgroups. Diamonds = point estimate and 95% CI for overall effects, with proportional reductions indicated alongside. Solid vertical line = hazard ratio of 1.0 (ie, no effect of treatment), and dotted vertical line = observed overall effect. DVT = deep venous thrombosis; VTE = venous thromboembolism; surg = surgical; med = medical; gyn = gynecological. The American Journal of Medicine 2009 122, 919-930DOI: (10.1016/j.amjmed.2009.03.026) Copyright © 2009 Elsevier Inc. Terms and Conditions

Figure 2 Proportional effects of unfractionated heparin (UFH) and low-molecular weight heparin (LMWH) on heparin-associated thrombocytopenia in patients who received treatment. Black squares = point estimates (with area proportional to number of events) and horizontal lines = 95% confidence interval (CI) for observed effects in different subgroups. Diamonds = point estimate and 95% CI for overall effects, with proportional reductions indicated alongside. Solid vertical line = hazard ratio of 1.0 (ie, no effect of treatment), and dotted vertical line = observed overall effect. DVT = deep venous thrombosis; PE = pulmonary embolism; VTE = venous thromboembolism. The American Journal of Medicine 2009 122, 919-930DOI: (10.1016/j.amjmed.2009.03.026) Copyright © 2009 Elsevier Inc. Terms and Conditions

Figure 3 Proportional effects of unfractionated heparin (UFH) and low-molecular weight heparin (LMWH) on heparin-associated thrombocytopenia in patients who received either treatment or prophylaxis. Black squares = point estimates (with area proportional to number of events) and horizontal lines = 95% confidence interval (CI) for observed effects in different subgroups. Diamonds = point estimate and 95% CI for overall effects, with proportional reductions indicated alongside. Solid vertical line = hazard ratio of 1.0 (ie, no effect of treatment), and dotted vertical line = observed overall effect. DVT = deep venous thrombosis; VTE = venous thromboembolism; PE = pulmonary embolism; surg = surgical; med = medical; gyn = gynecological. The American Journal of Medicine 2009 122, 919-930DOI: (10.1016/j.amjmed.2009.03.026) Copyright © 2009 Elsevier Inc. Terms and Conditions